Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
- PMID: 27959717
- DOI: 10.1056/NEJMoa1611688
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Abstract
Background: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.
Methods: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months.
Results: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49).
Conclusions: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .).
Comment in
-
Vascular disease: Ticagrelor not superior to clopidogrel for PAD.Nat Rev Cardiol. 2017 Jan;14(1):4-5. doi: 10.1038/nrcardio.2016.198. Epub 2016 Dec 1. Nat Rev Cardiol. 2017. PMID: 27905478 No abstract available.
-
Ticagrelor versus Clopidogrel in Peripheral Artery Disease.N Engl J Med. 2017 Apr 13;376(15):1487-8. doi: 10.1056/NEJMc1701197. N Engl J Med. 2017. PMID: 28402762 No abstract available.
-
Ticagrelor versus Clopidogrel in Peripheral Artery Disease.N Engl J Med. 2017 Apr 13;376(15):1487. doi: 10.1056/NEJMc1701197. N Engl J Med. 2017. PMID: 28406280 No abstract available.
-
Kein Vorteil für Ticagrelor bei PAVK.MMW Fortschr Med. 2017 May;159(9):42. doi: 10.1007/s15006-017-9643-0. MMW Fortschr Med. 2017. PMID: 28509023 German. No abstract available.
Similar articles
-
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.Eur J Vasc Endovasc Surg. 2018 Jan;55(1):109-117. doi: 10.1016/j.ejvs.2017.11.006. Epub 2017 Dec 20. Eur J Vasc Endovasc Surg. 2018. PMID: 29273390 Clinical Trial.
-
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.Circulation. 2017 Jan 17;135(3):241-250. doi: 10.1161/CIRCULATIONAHA.116.025880. Epub 2016 Nov 13. Circulation. 2017. PMID: 27840336 Clinical Trial.
-
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.Am Heart J. 2016 May;175:86-93. doi: 10.1016/j.ahj.2016.01.018. Epub 2016 Jan 28. Am Heart J. 2016. PMID: 27179727 Clinical Trial.
-
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.Cardiovasc Drugs Ther. 2013 Jun;27(3):239-45. doi: 10.1007/s10557-013-6444-2. Cardiovasc Drugs Ther. 2013. PMID: 23380983 Review.
-
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Thromb Haemost. 2013. PMID: 23197191 Review.
Cited by
-
Brazilian Society of Angiology and Vascular Surgery 2023 guidelines on the diabetic foot.J Vasc Bras. 2024 May 17;23:e20230087. doi: 10.1590/1677-5449.202300872. eCollection 2024. J Vasc Bras. 2024. PMID: 38803655 Free PMC article.
-
New Score Models for Predicting Bleeding and Ischemic of Ticagrelor Therapy in Patients with Diabetes Mellitus.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241254107. doi: 10.1177/10760296241254107. Clin Appl Thromb Hemost. 2024. PMID: 38780348 Free PMC article.
-
Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment.Curr Cardiol Rep. 2024 Jun;26(6):505-520. doi: 10.1007/s11886-024-02063-0. Epub 2024 May 14. Curr Cardiol Rep. 2024. PMID: 38743352 Review.
-
The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The "Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis" Registry.J Clin Med. 2024 Mar 28;13(7):1956. doi: 10.3390/jcm13071956. J Clin Med. 2024. PMID: 38610724 Free PMC article.
-
A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients-A Review PART II-Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory.J Clin Med. 2024 Mar 5;13(5):1508. doi: 10.3390/jcm13051508. J Clin Med. 2024. PMID: 38592348 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical